Showing results (871-880 of 3,354) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|October 4, 2019
Access to radiotherapy among circumpolar Inuit populationsJessica Chan, Jeppe Friborg, Mikhail Chernov, et al.
The Lancet. Oncology|October 5, 2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyCarmen D Herling, Kevin R Coombes, Axel Benner, et al.
The Lancet. Oncology|October 8, 2019
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyMyung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, et al.
The Lancet. Oncology|October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
The Lancet. Oncology|January 24, 2021
Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling studySathira Kasun Perera, Susannah Jacob, Brooke E Wilson, et al.
The Lancet. Oncology|January 21, 2021
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trialFrançois Quénet, Dominique Elias, Lise Roca, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
The Lancet. Oncology|February 4, 2021
Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization GroupRenée L Mulder, Anna Font-Gonzalez, Melissa M Hudson, et al.
The Lancet. Oncology|January 15, 2022
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trialDavid Cella, Robert J Motzer, Cristina Suarez, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Pageof 336